Looking ahead, ALX Oncology Holdings Inc. (NASDAQ:ALXO) CEO Jason Lettmann said that its multiple ongoing clinical studies are set to position the company for near- and long-term success.

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

ALX CEO Warren Stanyer will join Greenridge as president and director. The merger is also expected to yield significant cost ...